Generic Verdeso Availability
Last updated on Apr 10, 2025.
Verdeso is a brand name of desonide topical, approved by the FDA in the following formulation(s):
VERDESO (desonide - aerosol, foam;topical)
-
Manufacturer: ALMIRALL
Approval date: September 19, 2006
Strength(s): 0.05% (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Verdeso. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Microemulsion process and composition
Patent 8,460,641
Issued: June 11, 2013
Inventor(s): Larm Maria Graziella & Harding Ronald & Johnston Michael & Abram Albert Zorko & Vijayakumar Prema & Sun Phoebe
Assignee(s): Stiefel Research Australia Pty LtdAn oil-in-water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, comprising: a first part including at least one occlusive agent and one or more lipophilic surfactants dispersed throughout a second part including water and at least one hydrophilic surfactant, and a non-surfactant amphiphilic type compound, pharmaceutically active ingredient, and water. It has been found that if a non-surfactant amphiphilic type compound is added together with the second part as would conventionally be the case, a microemulsion or sub-micron emulsion is not formed, by adding the so called third part, phase assembly occurs at a lower temperature than would be expected and moreover, this phase appears to assist in maintaining the microemulsion or sub-micron emulsion characteristics of the formulation during storage at normal temperatures.
Patent expiration dates:
- August 13, 2027✓✓
- August 13, 2027
-
Microemulsion and sub-micron emulsion process and compositions
Patent 8,962,000
Issued: February 24, 2015
Inventor(s): Larm Maria Graziella & Harding Ronald & Johnston Michael & Abram Albert Zorko & Viyayakumar Prema & Sun Phoebe
Assignee(s): Stiefel West Coast LLCAn oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.
Patent expiration dates:
- August 31, 2025✓✓
- August 31, 2025
-
Microemulsion and sub-micron emulsion process and compositions
Patent 9,492,384
Issued: November 15, 2016
Inventor(s): Larm Maria Graziella & Harding Ronald & Johnston Michael & Abram Albert Zorko & Viyayakumar Prema & Sun Phoebe
Assignee(s): STIEFEL WEST COAST LLCAn oil in water microemulsion or sub-micron emulsion composition for dermal delivery of desonide is provided, along with a method of medical or cosmetic treatment of a dermal condition using the composition. The composition includes desonide; an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant and water; and a non-surfactant amphiphilic compound that is miscible in the water phase and added to the composition after formation of the microemulsion or sub-micron emulsion; wherein the desonide is in the water phase or both the water phase and the oil phase.
Patent expiration dates:
- August 31, 2025✓✓
- August 31, 2025
More about Verdeso (desonide topical)
- Verdeso consumer information
- Check interactions
- Compare alternatives
- Reviews (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical steroids
- Breastfeeding
- En español
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.